Alaproclate

CAS No. 60719-82-6

Alaproclate( —— )

Catalog No. M36270 CAS No. 60719-82-6

Alaproclate is a non-competitive NMDA receptor antagonist and a new selective 5-HT uptake inhibitor for the study of depression and dementia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Alaproclate
  • Note
    Research use only, not for human use.
  • Brief Description
    Alaproclate is a non-competitive NMDA receptor antagonist and a new selective 5-HT uptake inhibitor for the study of depression and dementia.
  • Description
    Alaproclate is a non-competitive NMDA receptor antagonist and a new selective 5-HT uptake inhibitor for the study of depression and dementia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    NMDAR
  • Recptor
    NMDAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    60719-82-6
  • Formula Weight
    255.74
  • Molecular Formula
    C13H18ClNO2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC(C)(C)CC1=CC=C(Cl)C=C1)C(N)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Radiprodil

    Radiprodil (RGH-896) is an orally active and selective NMDA NR2B receptors antagonist. It was a potential treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).

  • Ro 25-6981 Maleate

    Ro 25-6981 Maleate is a potent and selective activity-dependent NMDA receptor blocker, specifically targeting the NR2B subunit (IC50 values are 0.009 μM for NR1C/NR2B and 52 μM for NR1C/NR2A receptor subunit combinations).

  • Ibotenic acid

    Ibotenic acid has agonist activity at both the NMDA and trans-ACPD or metabotropic quisqualate receptors.